Variability of individual platelet reactivity over time in patients treated with clopidogrel: Insights from the ELEVATE-TIMI 56 trial

Journal of the American College of Cardiology

Volumn 64, Issue 4, 2014, Pages 361-368

  Hochholzer, Willibald ^a   Ruff, Christian T ^b   Mesa, Robert A ^b   Mattimore, John F ^b   Cyr, John F ^b   Lei, Lanyu ^c   Frelinger, Andrew L ^d   Michelson, Alan D ^d   Berg, David D ^b   Angiolillo, Dominick J ^e   O'Donoghue, Michelle L ^b   Sabatine, Marc S ^b   Mega, Jessica L ^b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

clopidogrel; nonresponder; platelet reactivity; variability

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

CLOPIDOGREL; NONRESPONDER; PLATELET REACTIVITY; VARIABILITY;

CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84904899573     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.051     Document Type: Article

References (30)

1. G.N. Levine, E.R. Bates, J.C. Blankenship American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
2. R.S. Wright, J.L. Anderson, and C.D. Adams et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 1920 1959
3. W. Hochholzer, D. Trenk, and D. Frundi et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
4. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
5. J.L. Mega, T. Simon, and J.P. Collet et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
6. T. Geisler, D. Grass, and B. Bigalke et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
7. W. Hochholzer, D. Trenk, and M.F. Fromm et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
8. D.J. Angiolillo, E. Bernardo, and C. Ramirez et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304
9. A.L. Frelinger 3rd, D.L. Bhatt, and R.D. Lee et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function J Am Coll Cardiol 61 2013 872 879
10. L. Bonello, U.S. Tantry, and R. Marcucci et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
11. W. Hochholzer, D. Trenk, and H.P. Bestehorn et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750
12. G.W. Stone, B. Witzenbichler, and G. Weisz et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
13. D.J. Angiolillo, S.B. Shoemaker, and B. Desai et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716
14. D. Trenk, W. Hochholzer, and B. Muller et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement EuroIntervention 4 2008 214 221
15. N. von Beckerath, A. Kastrati, and A. Wieczorek et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819
16. J.L. Mega, W. Hochholzer, and A.L. Frelinger 3rd et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
17. L. Bonello, L. Camoin-Jau, and S. Arques et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
18. M.J. Price, P.B. Berger, and P.S. Teirstein et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
19. S.S. Brar, J. ten Berg, and R. Marcucci et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
20. M.J. Price, D.J. Angiolillo, and P.S. Teirstein et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
21. D. Trenk, G.W. Stone, and M. Gawaz et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
22. R. Marcucci, A.M. Gori, and R. Paniccia et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
23. A.D. Michelson, A.L. Frelinger 3rd, and E. Braunwald et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
24. F. Rollini, A. Tello-Montoliu, and D.J. Angiolillo Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease Platelets 23 2012 537 551
25. J. Saw, E.H. Madsen, and S. Chan et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study J Am Coll Cardiol 52 2008 1826 1833
26. J. Jaitner, J. Stegherr, and T. Morath et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients Thromb Haemost 105 2011 107 112
27. M.E. Hevelow, S.M. McKenzie, and J.E. Siegel Reproducibility of platelet function testing Lab Hematol 13 2007 59 62
28. M.A. Refaai, E. Frenkel, and R. Sarode Platelet aggregation responses vary over a period of time in healthy controls Platelets 21 2010 460 463
29. G. Campo, G. Parrinello, and P. Ferraresi et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
30. J.P. Collet, T. Cuisset, and G. Range et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109